Kiora Pharmaceuticals Inc (KPRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Brian M. Strem
Employees:
11
1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY, UT, 84105
(781) 788-8869

Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is based in Salt Lake City, Utah.

Data derived from most recent annual or quarterly report
Market Cap 5.294 Million Shares Outstanding12.664 Million Avg 30-day Volume 640.603 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue1870.7991 Debt to Equity0.0397 EBITDA-8.066 Million
Price to Book Value3.2231 Operating Margin-68104.7765 Enterprise Value21.653 Million
Current Ratio0.974 EPS Growth0.206 Quick Ratio0.669
1 Yr BETA 0.6822 52-week High/Low 6.43 / 0.35 Profit Margin-67102.9107
Operating Cash Flow Growth10.261 Altman Z-Score-10.1134 Free Cash Flow to Firm -8.995 Million
View SEC Filings from KPRX instead.

View recent insider trading info

Funds Holding KPRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KPRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-05-31:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-23:
    Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-02-28:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-02-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-01-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DREXLER SUSAN L. INTERIM CFO

    • Officer
    0 2022-04-21 1

    ROMANO SARAH CHIEF FINANCIAL OFFICER

    • Officer
    22,746 2022-02-10 9

    CHANEY PAUL G

    • Director
    5,000 2022-02-01 1

    TYLE PRAVEEN

    • Director
    5,000 2022-02-01 1

    GAYRON KENNETH L

    • Director
    5,000 2022-02-01 1

    HOLLANDER DAVID

    • Director
    9,000 2022-02-01 2

    SHAPIRO ARON

    • Director
    5,000 2022-02-01 1

    STREM BRIAN M. PRESIDENT AND CEO

    • Officer
    • Director
    75,000 2022-02-01 4

    DANIELS ERIC JOSEPH CHIEF DEVELOPMENT OFFICER

    • Officer
    25,000 2022-02-01 4

    PARSONS ERIN

    • Director
    9,000 2022-02-01 2

    FROM STEPHEN EXECUTIVE CHAIRMAN

    • Officer
    • Director
    67,693 2022-01-05 7

    MANN BRENDA VP OF RESEARCH & DEVELOPMENT

    • Officer
    15,136 2021-11-02 5

    MANZO MICHAEL P. VP OF ENGINEERING

    • Officer
    15,378 2021-08-03 2

    ARMISTICE CAPITAL, LLC

    ARMISTICE CAPITAL MASTER FUND LTD.

    BOYD STEVEN

    • 10% Owner
    785,000 2021-07-30 2

    HANCOCK THOMAS

    • Director
    0 2021-02-01 0

    GOLDBERG MORTON

    • Director
    0 2021-02-01 0

    MALFROY-CAMINE BERNARD

    • Director
    0 2021-02-01 0

    OBERMAYR FRANZ ACTING CEO

    • Officer
    101,613 2021-02-01 0

    MAHER ILLYA KEITH

    • Director
    0 2020-01-10 0

    WIROSTKO BARBARA CHIEF MEDICAL OFFICER

    • Officer
    463,808 2019-08-06 0

    GREENLEAF PETER

    • Director
    0 2019-02-01 0

    GARANZINI MICHAEL CHIEF COMMERCIAL OFFICER

    • Officer
    196,250 2018-07-10 0

    BALLAND THOMAS

    • Director
    0 2017-06-21 0

    VENTECH CAPITAL II

    • 10% Owner
    1,431,814 2017-03-13 0

    BRENNEMAN RYAN RANDALL CHIEF FINANCIAL OFFICER

    • Officer
    0 2016-07-18 0

    CHAOUI MOUNIA

    • Director
    0 2016-03-29 0

    IPSA (INNOVEN PARTENAIRES S.A.)

    • 10% Owner
    4,729,211 2015-02-19 0

    FCPR VENTECH B

    • 10% Owner
    No longer subject to file 2015-02-19 0

    NATIXIS PRIVATE EQUITY

    • 10% Owner
    674,205 2015-02-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 22:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 21:45:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 21:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 20:45:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 20:15:04 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 19:45:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 19:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 18:45:04 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 18:15:04 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 17:45:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 17:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 16:45:04 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 16:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 15:45:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 15:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 14:45:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 14:15:03 UTC -21.7833 23.3533 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 13:45:03 UTC -27.1749 28.7449 400000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 13:15:03 UTC -27.1749 28.7449 350000
    KIORA PHARMACEUTICALS INC KPRX 2022-06-30 12:45:03 UTC -27.1749 28.7449 350000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments